SG11201505924TA - Factor viii polypeptide formulations - Google Patents

Factor viii polypeptide formulations

Info

Publication number
SG11201505924TA
SG11201505924TA SG11201505924TA SG11201505924TA SG11201505924TA SG 11201505924T A SG11201505924T A SG 11201505924TA SG 11201505924T A SG11201505924T A SG 11201505924TA SG 11201505924T A SG11201505924T A SG 11201505924TA SG 11201505924T A SG11201505924T A SG 11201505924TA
Authority
SG
Singapore
Prior art keywords
factor viii
viii polypeptide
polypeptide formulations
formulations
factor
Prior art date
Application number
SG11201505924TA
Inventor
Kevin Maloney
Ahmad Abdul-Fattah
Daniel Gage
Original Assignee
Biogen Ma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50771579&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201505924T(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Biogen Ma Inc filed Critical Biogen Ma Inc
Publication of SG11201505924TA publication Critical patent/SG11201505924TA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2833—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against MHC-molecules, e.g. HLA-molecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11201505924TA 2013-03-15 2014-03-14 Factor viii polypeptide formulations SG11201505924TA (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361800293P 2013-03-15 2013-03-15
US201361817085P 2013-04-29 2013-04-29
US201361829884P 2013-05-31 2013-05-31
US201361839477P 2013-06-26 2013-06-26
US201361863860P 2013-08-08 2013-08-08
US201361876927P 2013-09-12 2013-09-12
US201361879955P 2013-09-19 2013-09-19
US201361897742P 2013-10-30 2013-10-30
PCT/US2014/029354 WO2014144795A1 (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations

Publications (1)

Publication Number Publication Date
SG11201505924TA true SG11201505924TA (en) 2015-09-29

Family

ID=50771579

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11201505924TA SG11201505924TA (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations
SG10201805207QA SG10201805207QA (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201805207QA SG10201805207QA (en) 2013-03-15 2014-03-14 Factor viii polypeptide formulations

Country Status (21)

Country Link
US (3) US9623088B2 (en)
EP (3) EP4122487A1 (en)
JP (5) JP6330026B2 (en)
AU (3) AU2014228506A1 (en)
CA (1) CA2899737A1 (en)
CL (1) CL2015002720A1 (en)
DK (1) DK2968477T3 (en)
EA (2) EA201890671A1 (en)
ES (2) ES2776195T3 (en)
HK (1) HK1220617A1 (en)
HU (1) HUE047933T2 (en)
LT (1) LT2968477T (en)
PH (2) PH12015501801A1 (en)
PL (2) PL2968477T3 (en)
PT (2) PT2968477T (en)
RS (1) RS60003B1 (en)
SG (2) SG11201505924TA (en)
SI (1) SI2968477T1 (en)
TW (2) TWI629993B (en)
UY (1) UY35462A (en)
WO (1) WO2014144795A1 (en)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201907152YA (en) * 2009-12-06 2019-09-27 Bioverativ Therapeutics Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
TWI828269B (en) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 Factor ix polypeptide formulations
EA201890671A1 (en) * 2013-03-15 2019-01-31 Биовератив Терапьютикс Инк. DRUGS OF POLYPEPTIDE FACTOR VIII
CN107759694B (en) 2016-08-19 2023-01-13 安源医药科技（上海）有限公司 Bispecific antibody, preparation method and application thereof
CN106279437B (en) * 2016-08-19 2017-10-31 安源医药科技（上海）有限公司 Hyperglycosylated human coagulation factor VIII fusion proteins and preparation method thereof and purposes
WO2018102743A1 (en) 2016-12-02 2018-06-07 Bioverativ Therapeutics Inc. Methods of treating hemophilic arthropathy using chimeric clotting factors
MX2019006446A (en) 2016-12-02 2019-12-11 Bioverativ Therapeutics Inc Methods of inducing immune tolerance to clotting factors.
JP7039308B2 (en) * 2017-02-08 2022-03-22 三洋化成工業株式会社 Cell culture carrier
KR20200035130A (en) 2017-08-09 2020-04-01 바이오버라티브 테라퓨틱스 인크. Nucleic acid molecules and uses thereof
CN111655230A (en) * 2017-11-07 2020-09-11 拉尼医疗有限公司 Coagulation factor formulations delivered into intestinal tissue using swallowable drug delivery devices
US12030925B2 (en) 2018-05-18 2024-07-09 Bioverativ Therapeutics Inc. Methods of treating hemophilia A
BR112021002017A2 (en) 2018-08-09 2021-05-11 Bioverativ Therapeutics Inc. nucleic acid molecules and their uses for non-viral gene therapy
WO2020086686A2 (en) * 2018-10-23 2020-04-30 The Children's Hospital Of Philadelphia Compositions and methods for modulating factor viii function
JP7501875B2 (en) * 2019-02-28 2024-06-18 公立大学法人横浜市立大学 Composition for treating blood coagulation and/or complement disorders
EP3956456A1 (en) 2019-04-17 2022-02-23 Codiak BioSciences, Inc. Compositions of exosomes and aav
JP2022537200A (en) 2019-06-19 2022-08-24 バイオベラティブ セラピューティクス インコーポレイテッド Methods and compositions for treating hemophilia and low bone mineral density
KR20230159284A (en) * 2022-05-10 2023-11-21 주식회사 녹십자 A Novel Liquid Formulation for Plasma Protein
WO2023219379A1 (en) * 2022-05-10 2023-11-16 주식회사 녹십자 Novel liquid formulation for lyophilization of plasma protein

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4757006A (en) 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
CA1341174C (en) 1985-04-12 2001-01-30 John J. Toole Jr. Procoagulant proteins derived from factor viii: c
KR910006424B1 (en) 1985-08-21 1991-08-24 인코텍스 비.브이 Method of manufacturing knitted briefs
JP2525022B2 (en) 1986-01-03 1996-08-14 ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド VIII: Improved production method for c-factor protein
US5595886A (en) 1986-01-27 1997-01-21 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US5543502A (en) 1986-06-24 1996-08-06 Novo Nordisk A/S Process for producing a coagulation active complex of factor VIII fragments
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
CA1331157C (en) 1987-04-06 1994-08-02 Randal J. Kaufman Method for producing factor viii:c-type proteins
US6060447A (en) 1987-05-19 2000-05-09 Chiron Corporation Protein complexes having Factor VIII:C activity and production thereof
US6346513B1 (en) 1987-06-12 2002-02-12 Baxter Trading Gmbh Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
IL86693A (en) 1987-06-12 1994-06-24 Stichting Centraal Lab Proteins with factor VIII activity, process for their preparation using genetically engineered cells and pharmaceutical compositions containing them
DE3720246A1 (en) 1987-06-19 1988-12-29 Behringwerke Ag FACTOR VIII: C-LIKE MOLECULE WITH COAGULATION ACTIVITY
FR2619314B1 (en) 1987-08-11 1990-06-15 Transgene Sa FACTOR VIII ANALOG, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME
US4994371A (en) 1987-08-28 1991-02-19 Davie Earl W DNA preparation of Christmas factor and use of DNA sequences
US5004803A (en) 1988-11-14 1991-04-02 Genetics Institute, Inc. Production of procoagulant proteins
ATE135370T1 (en) 1988-12-22 1996-03-15 Kirin Amgen Inc CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR
DE69029799T2 (en) 1989-02-21 1997-05-28 Washington University, St. Louis, Mo. MODIFIED FORMS OF REPRODUCTION HORMONES
SE465222C5 (en) 1989-12-15 1998-02-10 Pharmacia & Upjohn Ab A recombinant human factor VIII derivative and process for its preparation
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
CA2106079C (en) 1991-03-15 2000-04-25 Robert C. Thompson Pegylation of polypeptides
FR2686899B1 (en) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa NOVEL BIOLOGICALLY ACTIVE POLYPEPTIDES, THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5364771A (en) 1992-04-07 1994-11-15 Emory University Hybrid human/porcine factor VIII
US5859204A (en) 1992-04-07 1999-01-12 Emory University Modified factor VIII
US6376463B1 (en) 1992-04-07 2002-04-23 Emory University Modified factor VIII
ES2154650T3 (en) * 1992-10-02 2001-04-16 Genetics Inst COMPOSITION THAT INCLUDES A FORMULATION WITH COAGULATION FACTOR VIII, PROCEDURE FOR THE PREPARATION AND USE OF A TENSIOACTIVE AS A STABILIZER.
US5563045A (en) 1992-11-13 1996-10-08 Genetics Institute, Inc. Chimeric procoagulant proteins
SE504074C2 (en) 1993-07-05 1996-11-04 Pharmacia Ab Protein preparation for subcutaneous, intramuscular or intradermal administration
IL113010A (en) * 1994-03-31 1999-10-28 Pharmacia & Upjohn Ab Pharmaceutical formulation comprising factor viii with an activity of at least 500iu/ml and an enhancer for improved subcutaneous intramuscular or intradermal administration
SE9503380D0 (en) 1995-09-29 1995-09-29 Pharmacia Ab Protein derivatives
US6458563B1 (en) 1996-06-26 2002-10-01 Emory University Modified factor VIII
US5763401A (en) 1996-07-12 1998-06-09 Bayer Corporation Stabilized albumin-free recombinant factor VIII preparation having a low sugar content
CA2225189C (en) 1997-03-06 2010-05-25 Queen's University At Kingston Canine factor viii gene, protein and methods of use
US6200560B1 (en) 1998-10-20 2001-03-13 Avigen, Inc. Adeno-associated virus vectors for expression of factor VIII by target cells
AU777972B2 (en) * 1999-02-22 2004-11-04 Baxalta GmbH Novel albumin-free factor VIII formulations
DK1252192T3 (en) 2000-02-11 2006-11-20 Merck Patent Gmbh Enhancement of the serum half-life of antibody-based fusion proteins
EP2261250B1 (en) 2001-12-21 2015-07-01 Human Genome Sciences, Inc. GCSF-Albumin fusion proteins
GB0207092D0 (en) 2002-03-26 2002-05-08 Sod Conseils Rech Applic Stable pharmaceutical composition containing factor VIII
US7041635B2 (en) 2003-01-28 2006-05-09 In2Gen Co., Ltd. Factor VIII polypeptide
US7348004B2 (en) 2003-05-06 2008-03-25 Syntonix Pharmaceuticals, Inc. Immunoglobulin chimeric monomer-dimer hybrids
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
DK2077121T3 (en) 2003-05-06 2011-06-06 Syntonix Pharmaceuticals Inc Coagulation factor VII-Fc chimeric proteins for the treatment of haemostatic disorders
US7211559B2 (en) 2003-10-31 2007-05-01 University Of Maryland, Baltimore Factor VIII compositions and methods
PL2298287T3 (en) 2003-12-19 2019-02-28 Novo Nordisk Health Care Ag Stabilised compositions of factor VII polypeptides
HUE050542T2 (en) 2004-11-12 2020-12-28 Bayer Healthcare Llc Site-directed modification of fviii
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US20080071063A1 (en) * 2006-02-03 2008-03-20 Medimmune, Inc. Protein Formulations
US8048848B2 (en) 2006-02-03 2011-11-01 Prolor Biotech Ltd. Long-acting interferons and derivatives thereof and methods thereof
CA2673459C (en) * 2006-12-22 2016-09-13 Stefan Schulte Modified coagulation factors with prolonged in vivo half-life
CA2691386C (en) 2007-06-21 2014-12-23 Technische Universitaet Muenchen Biological active proteins having increased in vivo and/or in vitro stability
US8239182B2 (en) 2007-12-04 2012-08-07 Spansion Llc Data transmission system-on-chip memory model based validation
US20100286067A1 (en) 2008-01-08 2010-11-11 Biogenerix Ag Glycoconjugation of polypeptides using oligosaccharyltransferases
WO2010115866A1 (en) * 2009-04-06 2010-10-14 Novo Nordisk A/S Targeted delivery of factor viii proteins to platelets
SG10201907152YA (en) * 2009-12-06 2019-09-27 Bioverativ Therapeutics Inc Factor viii-fc chimeric and hybrid polypeptides, and methods of use thereof
AU2012282875B2 (en) * 2011-07-08 2016-04-21 Bioverativ Therapeutics Inc. Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
CN103917554B (en) * 2011-10-18 2017-03-08 杰特有限公司 Method for improving the stability of the Factor IX of purification after reconstruct
JP2015527350A (en) * 2012-08-13 2015-09-17 ノヴォ ノルディスク アー／エス Factor VIII liquid formulation
EP3943102A1 (en) * 2012-10-30 2022-01-26 Bioverativ Therapeutics Inc. Methods of using fviii polypeptide
EA201890671A1 (en) * 2013-03-15 2019-01-31 Биовератив Терапьютикс Инк. DRUGS OF POLYPEPTIDE FACTOR VIII

Also Published As

Publication number Publication date
TWI629993B (en) 2018-07-21
EA201890671A1 (en) 2019-01-31
EA201591439A1 (en) 2016-03-31
JP2020186268A (en) 2020-11-19
PH12019502452A1 (en) 2021-02-08
US20210069300A1 (en) 2021-03-11
PL2968477T3 (en) 2020-06-15
US9623088B2 (en) 2017-04-18
EP3666283A1 (en) 2020-06-17
CA2899737A1 (en) 2014-09-18
UY35462A (en) 2014-10-31
EP2968477A1 (en) 2016-01-20
EA030357B1 (en) 2018-07-31
CL2015002720A1 (en) 2016-11-04
PH12015501801B1 (en) 2015-11-09
LT2968477T (en) 2020-03-10
TW201842930A (en) 2018-12-16
EP3666283B1 (en) 2022-06-08
JP2018123161A (en) 2018-08-09
WO2014144795A1 (en) 2014-09-18
JP7240457B2 (en) 2023-03-15
RS60003B1 (en) 2020-04-30
JP2016516722A (en) 2016-06-09
AU2014228506A1 (en) 2015-08-13
PT3666283T (en) 2022-09-13
TW201501722A (en) 2015-01-16
US20140308280A1 (en) 2014-10-16
PT2968477T (en) 2020-03-11
HK1220617A1 (en) 2017-05-12
EP2968477B1 (en) 2019-12-04
US10786554B2 (en) 2020-09-29
JP6330026B2 (en) 2018-05-23
AU2021277601A1 (en) 2021-12-23
SI2968477T1 (en) 2020-04-30
US20170281734A1 (en) 2017-10-05
PL3666283T3 (en) 2022-10-03
SG10201805207QA (en) 2018-07-30
PH12015501801A1 (en) 2015-11-09
EP4122487A1 (en) 2023-01-25
DK2968477T3 (en) 2020-03-09
HUE047933T2 (en) 2020-05-28
ES2776195T3 (en) 2020-07-29
JP6934994B2 (en) 2021-09-15
AU2019202656A1 (en) 2019-05-09
AU2019202656B2 (en) 2021-09-02
TWI690325B (en) 2020-04-11
JP2021181491A (en) 2021-11-25
JP2023060146A (en) 2023-04-27
ES2926798T3 (en) 2022-10-28

Similar Documents

Publication Publication Date Title
HK1220617A1 (en) Factor viii polypeptide formulations viii
EP3065716C0 (en) Formulations
HK1220697A1 (en) Peptide compositions
HK1220619A1 (en) Factor ix polypeptide formulations ix
HRP20180452T1 (en) Peptides
HK1213273A1 (en) Recombinant factor viii formulations viii
HK1220366A1 (en) Protein formulations
HK1211596A1 (en) Peptide
HK1211595A1 (en) Peptide
GB201315130D0 (en) Peptides
GB201316660D0 (en) Peptides
GB201300381D0 (en) Peptides